Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy

Journal of Clinical Immunology

Volumn 32, Issue 3, 2012, Pages 632-646

  Veuillen, Caroline ^a,b   Aurran Schleinitz, Thérèse ^c   Castellano, Rémy ^a,c   Rey, Jérôme ^a,b,c   Mallet, Françoise ^a,c   Orlanducci, Florence ^a,c   Pouyet, Laurent ^a,c   Just Landi, Sylvaine ^a,c   Coso, Diane ^c   Ivanov, Vadim ^c   Carcopino, Xavier ^a,b   Bouabdallah, Réda ^c   Collette, Yves ^a,c   Fauriat, Cyril ^a   Olive, Daniel ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

cell interactions; CLL; cytotoxicity; immunotherapy; NK cells; NK receptors

Indexed keywords

CD48 ANTIGEN; CELL SURFACE PROTEIN; HLA A ANTIGEN; HLA ANTIGEN; HLA E ANTIGEN; HLA G ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; NECTIN 1; NECTIN 2; NUCLEAR FACTOR; NUCLEAR FACTOR BAT3; PROTEIN B7 H6; PROTEIN MICA B; PROTEIN ULBP1; PROTEIN ULBP2; PROTEIN ULBP3; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL INTERACTION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LOW DRUG DOSE; MALE; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; UPREGULATION;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NEOPLASM TRANSPLANTATION;

EID: 84861480726     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9624-5     Document Type: Article

References (74)

1. Cramer P, Hallek M, et al. Prognostic factors in chronic lymphocytic leukemia - what do we need to know? Nat Rev Clin Oncol. 2011;8:38-47.
2. Packham G, Stevenson FK, et al. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology. 2005;114:441-9. (Pubitemid 40478137)
3. Kolb J-P, Kern C, Quiney C, Roman V, Billard C, et al. Reestablishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3:261-86. (Pubitemid 37540859)
4. Dasanu CA, Alexandrescu DT, et al. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed. 2007;9:35.
5. Hamblin AD, Hamblin TJ, et al. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87:49-62.
6. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do K-A, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-80.
7. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-74.
8. Gribben JG, O'Brien S, et al. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011;29:544-50.
9. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747-53. (Pubitemid 46606321)
10. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Brüggemann M, Pott C, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004;104:2600-2.
11. Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011;117 (20):4679-88.
12. Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee M-S, Korbling M, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007;137:355-63. (Pubitemid 46650260)
13. Ben-Bassat I, Raanani P, Gale RP, et al. Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant. 2007;39:441-6. (Pubitemid 46605201)
14. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-100. (Pubitemid 34229476)
15. Pegram HJ, Ritchie DS, Smyth MJ, Wiernik A, Prince HM, Darcy PK, et al. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk Res. 2011;35:14-21.
16. Hallek M, Pflug N, et al. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev. 2011;25:1-9.
17. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010;116:3705-14.
18. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44-9.
19. Biassoni R. Human natural killer receptors, co-receptors, and their ligands. Curr Protoc Immunol 2009; Chapter 14: Unit 14.10.
20. Cooper MA, Fehniger TA, Caligiuri MA, et al. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-40. (Pubitemid 33043908)
21. Fauriat C, Long EO, Ljunggren H-G, Bryceson YT, et al. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115:2167-76.
22. De Maria A, Bozzano F, Cantoni C, Moretta L, et al. Revisiting human natural killer cell subset function revealed cytolytic CD56 (dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA. 2011;108:728-32.
23. Barber DF, Long EO, et al. Coexpression of CD58 or CD48 with intercellular adhesion molecule 1 on target cells enhances adhesion of resting NK cells. J Immunol. 2003;170:294-9. (Pubitemid 36026152)
24. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-74. (Pubitemid 40563170)
25. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22:998-1006. (Pubitemid 351689882)
26. Jewell AP, Worman CP, Giles FJ, Goldstone AH, Lydyard PM, et al. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells. Leuk Lymphoma. 1992;7:473-80.
27. Spitz DL, Zucker-Franklin D, Nabi ZF, et al. Unmasking of cryptic natural killer (NK) cell recognition sites on chronic lymphocytic leukemia lymphocytes. Am J Hematol. 1988;28:155-61.
28. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H, et al. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009;33:1255-9.
29. Ziegler HW, Kay NE, Zarling JM, et al. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer. 1981;27:321-7. (Pubitemid 11155351)
30. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD, et al. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol. 1996;96:16-23. (Pubitemid 26187968)
31. Kay NE, Zarling J, et al. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. Am J Hematol. 1987;24:161-7. (Pubitemid 17020783)
32. Kay NE, Zarling JM, et al. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood. 1984;63:305-9. (Pubitemid 14188874)
33. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-8.
34. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-56.
35. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, et al. The immunological profile of Bcell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-5. (Pubitemid 24323778)
36. Bryceson YT, March ME, Barber DF, Ljunggren H-G, Long EO, et al. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med. 2005;202:1001-12. (Pubitemid 41396899)
37. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, et al. Human leukocyte antigen-Bassociated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007;27:965-74.
38. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206:1495-503.
39. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190:1505-16.
40. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PEM, Simone R, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011;117:5463-72.
41. Cartron G, Watier H, Golay J, Solal-Celigny P, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635-42. (Pubitemid 39434941)
42. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by transretinoic acid. Cancer Res. 2004;64:9172-9. (Pubitemid 39665533)
43. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2Dexpressing cells. Leukemia. 2007;21:2103-8. (Pubitemid 47423800)
44. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIRHLA class I specificities. Blood. 2008;111:1428-36. (Pubitemid 351213430)
45. Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008;272:110-21.
46. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR, et al. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia. 2009;23:641-8.
47. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A, et al. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res. 2007;31:1393-402. (Pubitemid 47212430)
48. Tang K-F, He C-X, Zeng G-L, Wu J, Song G-B, Shi Y-S, et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine. Biochem Biophys Res Commun. 2008;370:578-83.
49. Béziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, Combadière B, et al. CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J Immunol. 2011;186:6753-61.
50. Björkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116:3853-64.
51. Fauriat C, Ivarsson MA, Ljunggren H-G, Malmberg K-J, Michaëlsson J, et al. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010;115:1166-74.
52. Andersson S, Fauriat C, Malmberg J-A, Ljunggren H-G, Malmberg K-J, et al. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood. 2009;114:95-104.
53. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci M-J, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99:3661-7. (Pubitemid 34534536)
54. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren H-G, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol. 2009;183:4921-30.
55. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71:6621-32.
56. Mamessier E, Sylvain A, ThibultM-L, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121:3609-22.
57. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195:343-51. (Pubitemid 34461492)
58. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood. 2005;106:566-71. (Pubitemid 40981252)
59. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, et al. Analysis of CD16 + CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011;25:101-9.
60. Roda-Navarro P, Vales-Gomez M, Chisholm SE, Reyburn HT, et al. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc Natl Acad Sci U S A. 2006;103:11258-63. (Pubitemid 44156506)
61. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood. 2005;106:1711-7. (Pubitemid 41208585)
62. Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R et. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 2011.
63. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol. 2003;171:6891-9. (Pubitemid 37532125)
64. Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela J-M, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol. 2006;176:5108-16.
65. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR, et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 2004;114:560-8. (Pubitemid 39572106)
66. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 2004;103:3122-30. (Pubitemid 38451690)
67. Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, et al. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells. Cancer Immunol Immunother. 2009;58:855-65.
68. Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667-77.
69. Sola C, André P, Lemmers C, Fuseri N, Bonnafous C, Bléry M, et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci USA. 2009;106:12879-84.
70. Malmberg K-J, Bryceson YT, Carlsten M, Andersson S, Björklund A, Björkström NK, et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother. 2008;57:1541-52.
71. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L, et al. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008;9:486-94. (Pubitemid 351560517)
72. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280-8. (Pubitemid 38263720)
73. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006;177:7435-43. (Pubitemid 44715114)
74. Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica. 2010;95:329-32.